Hester Biosciences Limited (HESTERBIO.BO)
INR 2469.0
(1.32%)
INR 2469.0
(1.32%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 3.04 Billion INR | 14.45% |
| 2022 | 2.66 Billion INR | 13.23% |
| 2021 | 2.35 Billion INR | 9.65% |
| 2020 | 2.14 Billion INR | 16.95% |
| 2019 | 1.83 Billion INR | 2.92% |
| 2018 | 1.78 Billion INR | 30.99% |
| 2017 | 1.35 Billion INR | 10.42% |
| 2016 | 1.23 Billion INR | 22.26% |
| 2015 | 1 Billion INR | 11.84% |
| 2014 | 900.37 Million INR | 30.4% |
| 2013 | 690.48 Million INR | 6.06% |
| 2012 | 651.04 Million INR | 34.89% |
| 2011 | 482.63 Million INR | 14.99% |
| 2010 | 419.71 Million INR | 11.83% |
| 2009 | 375.32 Million INR | 24.44% |
| 2008 | 301.59 Million INR | -7.58% |
| 2007 | 326.33 Million INR | 49.5% |
| 2006 | 218.27 Million INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 836.92 Million INR | 1.73% |
| 2024 Q1 | 822.67 Million INR | 3.8% |
| 2023 Q4 | 792.55 Million INR | 18.32% |
| 2023 FY | 3.04 Billion INR | 14.45% |
| 2023 Q1 | 878.53 Million INR | 30.54% |
| 2023 Q3 | 669.83 Million INR | -4.93% |
| 2023 Q2 | 704.55 Million INR | -19.8% |
| 2022 Q3 | 749.44 Million INR | 2.45% |
| 2022 Q4 | 672.99 Million INR | -10.2% |
| 2022 FY | 2.66 Billion INR | 13.23% |
| 2022 Q1 | 506.95 Million INR | -10.23% |
| 2022 Q2 | 731.53 Million INR | 44.3% |
| 2021 Q4 | 564.69 Million INR | 1.4% |
| 2021 FY | 2.35 Billion INR | 9.65% |
| 2021 Q2 | 626.62 Million INR | 4.11% |
| 2021 Q3 | 556.89 Million INR | -11.13% |
| 2021 Q1 | 601.86 Million INR | -6.22% |
| 2020 Q4 | 641.75 Million INR | 12.8% |
| 2020 FY | 2.14 Billion INR | 16.95% |
| 2020 Q3 | 568.94 Million INR | 6.52% |
| 2020 Q2 | 534.1 Million INR | 34.02% |
| 2020 Q1 | 398.53 Million INR | -8.64% |
| 2019 Q3 | 506.92 Million INR | 14.69% |
| 2019 Q4 | 436.2 Million INR | -13.95% |
| 2019 FY | 1.83 Billion INR | 2.92% |
| 2019 Q1 | 447.58 Million INR | -10.04% |
| 2019 Q2 | 441.98 Million INR | -1.25% |
| 2018 Q3 | 457.32 Million INR | 6.92% |
| 2018 Q2 | 427.73 Million INR | 7.45% |
| 2018 Q1 | 398.08 Million INR | 0.0% |
| 2018 FY | 1.78 Billion INR | 30.99% |
| 2018 Q4 | 497.53 Million INR | 8.79% |
| 2017 FY | 1.35 Billion INR | 10.42% |
| 2016 FY | 1.23 Billion INR | 22.26% |
| 2015 FY | 1 Billion INR | 11.84% |
| 2014 FY | 900.37 Million INR | 30.4% |
| 2013 FY | 690.48 Million INR | 6.06% |
| 2012 Q4 | 170.23 Million INR | -8.97% |
| 2012 FY | 651.04 Million INR | 34.89% |
| 2012 Q1 | 138.43 Million INR | 0.0% |
| 2012 Q2 | 155.35 Million INR | 12.22% |
| 2012 Q3 | 187.01 Million INR | 20.38% |
| 2011 FY | 482.63 Million INR | 14.99% |
| 2010 FY | 419.71 Million INR | 11.83% |
| 2009 FY | 375.32 Million INR | 24.44% |
| 2008 FY | 301.59 Million INR | -7.58% |
| 2007 FY | 326.33 Million INR | 49.5% |
| 2006 FY | 218.27 Million INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Ajanta Pharma Limited | 42.08 Billion INR | 92.764% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | 27.701% |
| Sigachi Industries Limited | 3.98 Billion INR | 23.664% |
| Bal Pharma Limited | 3.39 Billion INR | 10.222% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | 76.224% |
| Medico Remedies Limited | 1.44 Billion INR | -110.147% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -191.892% |
| Venus Remedies Limited | 5.91 Billion INR | 48.509% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -303.13% |
| Alpa Laboratories Limited | 1.08 Billion INR | -180.071% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 81.916% |
| Shilpa Medicare Limited | 11.51 Billion INR | 73.555% |
| Aarti Drugs Limited | 25.28 Billion INR | 87.956% |
| Lupin Limited | 200.1 Billion INR | 98.478% |
| Aurobindo Pharma Limited | 287.04 Billion INR | 98.939% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 98.399% |
| Windlas Biotech Limited | 6.3 Billion INR | 51.733% |
| Suven Life Sciences Limited | 116.92 Million INR | -2504.538% |
| Eris Lifesciences Limited | 20.09 Billion INR | 84.842% |
| Valiant Laboratories Limited | 1.82 Billion INR | -67.28% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.84 Billion INR | 91.259% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | 75.408% |
| Ipca Laboratories Limited | 76.22 Billion INR | 96.005% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | 60.461% |
| Achyut Healthcare Limited | 61.36 Million INR | -4862.538% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 99.372% |
| Bajaj HealthCare Limited | 4.73 Billion INR | 35.671% |
| RPG Life Sciences Limited | 5.82 Billion INR | 47.677% |
| Mankind Pharma Limited | 103.34 Billion INR | 97.053% |
| Laurus Labs Limited | 50.01 Billion INR | 93.911% |
| Piramal Pharma Limited | 81.71 Billion INR | 96.273% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | -17.475% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 97.128% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 95.017% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 97.422% |
| Unichem Laboratories Limited | 16.57 Billion INR | 81.625% |
| Sequent Scientific Limited | 13.69 Billion INR | 77.766% |
| Novartis India Limited | 3.35 Billion INR | 9.11% |
| Wanbury Limited | 5.75 Billion INR | 47.095% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | 71.033% |
| Wockhardt Limited | 27.89 Billion INR | 89.08% |
| Themis Medicare Limited | 3.81 Billion INR | 20.226% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | -45.924% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 95.457% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 86.662% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 98.909% |
| Divi's Laboratories Limited | 78.45 Billion INR | 96.118% |
| NATCO Pharma Limited | 40.02 Billion INR | 92.39% |
| Gufic Biosciences Limited | 8.06 Billion INR | 62.246% |
| IOL Chemicals and Pharmaceuticals Limited | 21.18 Billion INR | 85.628% |
| Ind-Swift Limited | 5.02 Billion INR | 39.39% |
| Procter & Gamble Health Limited | 11.51 Billion INR | 73.547% |
| FDC Limited | 19.42 Billion INR | 84.326% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -504.0% |
| Granules India Limited | 45.06 Billion INR | 93.242% |
| Medicamen Biotech Limited | 1.79 Billion INR | -69.847% |
| Alkem Laboratories Limited | 126.67 Billion INR | 97.596% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | 76.493% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -660.694% |
| Brooks Laboratories Limited | 794.86 Million INR | -283.144% |
| Megasoft Limited | 373.95 Million INR | -714.396% |
| ZIM Laboratories Limited | 3.67 Billion INR | 17.113% |
| Strides Pharma Science Limited | 40.51 Billion INR | 92.482% |
| Neuland Laboratories Limited | 15.58 Billion INR | 80.46% |
| Morepen Laboratories Limited | 17.01 Billion INR | 82.106% |
| Hikal Limited | 17.84 Billion INR | 82.935% |
| Indoco Remedies Limited | 17.89 Billion INR | 82.981% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 83.225% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -97.28% |
| Mangalam Drugs & Organics Limited | 3.68 Billion INR | 17.376% |